Department of Radiology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan.
Department of Radiology, Fujieda Heisei Memorial Hospital, Shizuoka, Japan.
Int J Clin Oncol. 2019 Feb;24(2):161-167. doi: 10.1007/s10147-018-1339-7. Epub 2018 Aug 11.
PURPOSE/OBJECTIVE(S): Radiosurgery plus whole-brain radiotherapy (WBRT) has been reported to be useful for patients with ≤ 4 brain metastases (BM), but we hypothesized that similar treatment may be applicable to patients with ≥ 5 BM with or without meningeal dissemination. The purpose of this study was to evaluate the efficacy and toxicity of low-dose Gamma Knife (GK) followed by WBRT for patients with advanced BM.
MATERIALS/METHODS: Major eligibility criteria for this phase II study were: (1) ≥ 5 BM with or without meningeal dissemination and (2) the largest tumor diameter ≤ 4 cm. During 2013-2016, 40 patients (13 men and 27 women) entered the study. Nineteen had meningeal dissemination. The GK dose was 12 Gy at the periphery when the longest diameter was 3-4 cm and 14 Gy when it was < 3 cm. The WBRT dose to the isocenter was 30 Gy in 10 fractions, or 37.5 Gy in 15 fractions for two patients, with an expected survival of > 12 months. The median number of target BM was 17.5.
After GK plus WBRT for 40 patients, 31 did not develop further intracranial recurrence until death or last follow-up, whereas 9 developed recurrence. With a follow-up period up to 24 months, the overall survival rate was 36% at 12 months and median survival time was 8 months. The cumulative incidence of intracranial recurrence was 25% at 12 months. Toxicity was considered acceptable.
Treatment with low-dose GK followed by WBRT for advanced-stage BM appeared to contribute to local control.
立体定向放射外科(SRS)联合全脑放疗(WBRT)已被报道对≤4 个脑转移瘤(BM)患者有效,但我们假设类似的治疗方法可能适用于有或无脑膜播散的≥5 个 BM 患者。本研究的目的是评估低剂量伽玛刀(GK)联合 WBRT 治疗晚期 BM 患者的疗效和毒性。
本 II 期研究的主要入选标准为:(1)有或无脑膜播散的≥5 个 BM;(2)最大肿瘤直径≤4cm。2013 年至 2016 年期间,共有 40 例患者(13 例男性,27 例女性)入组该研究。19 例有脑膜播散。GK 剂量为最长直径 3-4cm 时周边 12Gy,最长直径<3cm 时 14Gy。WBRT 等中心剂量为 30Gy/10 次,2 例患者为 37.5Gy/15 次,预计生存时间>12 个月。目标 BM 的中位数为 17.5 个。
40 例患者接受 GK 联合 WBRT 治疗后,31 例在死亡或末次随访前未发生进一步颅内复发,9 例发生复发。随访时间最长达 24 个月,12 个月时总生存率为 36%,中位生存时间为 8 个月。12 个月时颅内复发累积发生率为 25%。毒性反应可接受。
低剂量 GK 联合 WBRT 治疗晚期 BM 似乎有助于局部控制。